Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Icecure Medical ( (ICCM) ) has issued an announcement.
IceCure Medical announced preliminary unaudited financial results for the first half of 2025, revealing lower product sales due to delayed shipments and the absence of revenue from a previous agreement with Terumo Corporation in Japan. The company expects a higher net loss compared to the same period in 2024, although operating expenses are not anticipated to be materially affected. Additionally, IceCure commenced a rights offering on July 10, 2025, aiming to raise $10 million by allowing shareholders to purchase units comprising shares and warrants. The proceeds will be used to repay a bridge loan and for general corporate purposes. Epoch Partner Investments Limited, the largest shareholder, has committed to fully participate in the offering.
The most recent analyst rating on (ICCM) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.
Icecure Medical’s overall stock score reflects significant financial challenges, including persistent losses and cash flow issues. While positive developments with the FDA and regional sales provide some optimism, technical and valuation challenges persist. The company’s efforts to gain regulatory approval and expand its market presence are critical to improving its financial outlook.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors, with a primary focus on breast, kidney, bone, and lung cancer. The company’s minimally invasive technology serves as a safe and effective alternative to surgical tumor removal and is marketed globally, including in the U.S., Europe, and Asia.
Average Trading Volume: 267,693
Technical Sentiment Signal: Buy
Current Market Cap: $63.74M
For an in-depth examination of ICCM stock, go to TipRanks’ Overview page.